U.S. Markets closed

OxySure Therapeutics, Inc. (OXYS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00495-0.00005 (-1.00000%)
At close: 12:54PM EDT
People also watch
SNWVPSIDPBIOPPCHNVIV
Full screen
Previous Close0.00500
Open0.00495
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.00495 - 0.00495
52 Week Range0.00200 - 0.03000
Volume2,986
Avg. Volume18,972
Market Cap200.01k
Beta0.55
PE Ratio (TTM)-0.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • OxySure Systems, Inc. Earnings Q3, 2015
    Capital Cube2 years ago

    OxySure Systems, Inc. Earnings Q3, 2015

    Click here to see latest analysisOxySure Systems, Inc. reports financial results for the quarter ended September 30, 2015.We analyze the earnings along side the following peers of OxySure Systems, Inc. – Inogen, Inc., Hansen Medical, Inc. and Ekso Bionics Holdings, Inc. (INGN-US, HNSN-US and EKSO-US) that have also reported for this period.HighlightsSummary numbers: Revenues of […] (Read more...) The post OxySure Systems, Inc. Earnings Q3, 2015 appeared first on CapitalCube.

  • OxySure Systems, Inc. Earnings Q2, 2015
    Capital Cube2 years ago

    OxySure Systems, Inc. Earnings Q2, 2015

    OxySure Systems, Inc. reports preliminary financial results for the quarter ended June 30, 2015.We analyze the earnings along side the following peers of OxySure Systems, Inc. – Inogen, Inc., Hansen Medical, Inc. and Ekso Bionics Holdings, Inc. (INGN-US, HNSN-US and EKSO-US) that have also reported for this period.HighlightsSummary numbers: Revenues of USD 1.05 million, Net (Read more...) The post OxySure Systems, Inc. Earnings Q2, 2015 appeared first on CapitalCube.

  • Zacks Small Cap Research2 years ago

    OXYS: Gaining Momentum with Revenue Growth in 2Q 2015

    OxySure sold $2.7 million in convertible preferred stock and $300,000 in two convertible notes, totaling $3 million. OxySure received net proceeds comprising a first tranche of $1 million in part from the issuance of 385,000 shares of newly created Series C convertible preferred stock with a stated value of $2.00 per share in cash at the closing on June 30, 2015. A second tranche, comprised of the remaining $2 million (issued as 1.05 million shares of newly created series D convertible preferred stock) will be placed in an escrow account to be released to OxySure upon an uplisting to a national exchange such as NasdaqCM or NYSEMKT.